



T Cell Antigen Gp39 Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-19	115	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global T Cell Antigen Gp39 market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for T Cell Antigen Gp39 is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for T Cell Antigen Gp39 is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for T Cell Antigen Gp39 is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of T Cell Antigen Gp39 include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global T Cell Antigen Gp39 market in terms of revenue (US\$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

T Cell Antigen Gp39 Market by Company

Biogen, Inc.

XL-protein GmbH

Targovax AS

MedImmune, LLC

Juno Therapeutics Inc.

ImmuNext, Inc.

eTheRNA Immunotherapies NV

Bristol-Myers Squibb Company

T Cell Antigen Gp39 Segment by Type

ECI-006

Hepatitis B Vaccine

ISF-35

INX-021

Others

T Cell Antigen Gp39 Segment by Application

Graft Versus Host Disease

Pancreatic Cancer

Breast Cancer

Bladder Cancer

Others

T Cell Antigen Gp39 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks

on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Antigen Gp39 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of T Cell Antigen Gp39 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Antigen Gp39.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of T Cell Antigen Gp39 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of T Cell Antigen Gp39 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global T Cell Antigen Gp39 Market Size (2021-2032)
 - 2.2.2 Global T Cell Antigen Gp39 Sales (2021-2032)
 - 2.2.3 Global T Cell Antigen Gp39 Market Average Price (2021-2032)
- 2.3 T Cell Antigen Gp39 by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 ECI-006
 - 2.3.3 Hepatitis B Vaccine
 - 2.3.4 ISF-35
 - 2.3.5 INX-021
 - 2.3.6 Others
- 2.4 T Cell Antigen Gp39 by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Graft Versus Host Disease
 - 2.4.3 Pancreatic Cancer
 - 2.4.4 Breast Cancer
 - 2.4.5 Bladder Cancer
 - 2.4.6 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global T Cell Antigen Gp39 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global T Cell Antigen Gp39 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global T Cell Antigen Gp39 Revenue of Manufacturers (2021-2026)
- 3.4 Global T Cell Antigen Gp39 Average Price by Manufacturers (2021-2026)
- 3.5 Global T Cell Antigen Gp39 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of T Cell Antigen Gp39, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of T Cell Antigen Gp39, Product Type & Application
- 3.8 Global Manufacturers of T Cell Antigen Gp39, Established Date
- 3.9 Global T Cell Antigen Gp39 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Biogen, Inc.
 - 4.1.1 Biogen, Inc. Company Information
 - 4.1.2 Biogen, Inc. Business Overview

- 4.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
- 4.1.5 Biogen, Inc. Recent Developments
- 4.2 XL-protein GmbH
 - 4.2.1 XL-protein GmbH Company Information
 - 4.2.2 XL-protein GmbH Business Overview
 - 4.2.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
 - 4.2.5 XL-protein GmbH Recent Developments
- 4.3 Targovax AS
 - 4.3.1 Targovax AS Company Information
 - 4.3.2 Targovax AS Business Overview
 - 4.3.3 Targovax AS T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Targovax AS T Cell Antigen Gp39 Product Portfolio
 - 4.3.5 Targovax AS Recent Developments
- 4.4 MedImmune, LLC
 - 4.4.1 MedImmune, LLC Company Information
 - 4.4.2 MedImmune, LLC Business Overview
 - 4.4.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
 - 4.4.5 MedImmune, LLC Recent Developments
- 4.5 Juno Therapeutics Inc.
 - 4.5.1 Juno Therapeutics Inc. Company Information
 - 4.5.2 Juno Therapeutics Inc. Business Overview
 - 4.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
 - 4.5.5 Juno Therapeutics Inc. Recent Developments
- 4.6 ImmuNext, Inc.
 - 4.6.1 ImmuNext, Inc. Company Information
 - 4.6.2 ImmuNext, Inc. Business Overview
 - 4.6.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
 - 4.6.5 ImmuNext, Inc. Recent Developments
- 4.7 eTheRNA Immunotherapies NV
 - 4.7.1 eTheRNA Immunotherapies NV Company Information
 - 4.7.2 eTheRNA Immunotherapies NV Business Overview
 - 4.7.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
 - 4.7.5 eTheRNA Immunotherapies NV Recent Developments
- 4.8 Bristol-Myers Squibb Company
 - 4.8.1 Bristol-Myers Squibb Company Company Information
 - 4.8.2 Bristol-Myers Squibb Company Business Overview
 - 4.8.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
 - 4.8.5 Bristol-Myers Squibb Company Recent Developments

5 Global T Cell Antigen Gp39 Market Scenario by Region

- 5.1 Global T Cell Antigen Gp39 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global T Cell Antigen Gp39 Sales by Region: 2021-2032

- 5.2.1 Global T Cell Antigen Gp39 Sales by Region: 2021-2026
- 5.2.2 Global T Cell Antigen Gp39 Sales by Region: 2027-2032
- 5.3 Global T Cell Antigen Gp39 Revenue by Region: 2021-2032
 - 5.3.1 Global T Cell Antigen Gp39 Revenue by Region: 2021-2026
 - 5.3.2 Global T Cell Antigen Gp39 Revenue by Region: 2027-2032
- 5.4 North America T Cell Antigen Gp39 Market Facts & Figures by Country
 - 5.4.1 North America T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America T Cell Antigen Gp39 Sales by Country (2021-2032)
 - 5.4.3 North America T Cell Antigen Gp39 Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
- 5.5 Europe T Cell Antigen Gp39 Market Facts & Figures by Country
 - 5.5.1 Europe T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe T Cell Antigen Gp39 Sales by Country (2021-2032)
 - 5.5.3 Europe T Cell Antigen Gp39 Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Netherlands
- 5.6 Asia Pacific T Cell Antigen Gp39 Market Facts & Figures by Country
 - 5.6.1 Asia Pacific T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific T Cell Antigen Gp39 Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific T Cell Antigen Gp39 Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 China Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America T Cell Antigen Gp39 Market Facts & Figures by Country
 - 5.7.1 South America T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America T Cell Antigen Gp39 Sales by Country (2021-2032)
 - 5.7.3 South America T Cell Antigen Gp39 Revenue by Country (2021-2032)
 - 5.7.4 Mexico
 - 5.7.5 Brazil
 - 5.7.6 Argentina
- 5.8 Middle East and Africa T Cell Antigen Gp39 Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2021-2032)
 - 5.8.4 Turkey
 - 5.8.5 Saudi Arabia
 - 5.8.6 UAE

6 Segment by Type

- 6.1 Global T Cell Antigen Gp39 Sales by Type (2021-2032)
 - 6.1.1 Global T Cell Antigen Gp39 Sales by Type (2021-2032) & (K Units)

6.1.2 Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2032)

6.2 Global T Cell Antigen Gp39 Revenue by Type (2021-2032)

6.2.1 Global T Cell Antigen Gp39 Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2032)

6.3 Global T Cell Antigen Gp39 Price by Type (2021-2032)

7 Segment by Application

7.1 Global T Cell Antigen Gp39 Sales by Application (2021-2032)

7.1.1 Global T Cell Antigen Gp39 Sales by Application (2021-2032) & (K Units)

7.1.2 Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2032)

7.2 Global T Cell Antigen Gp39 Revenue by Application (2021-2032)

7.2.1 Global T Cell Antigen Gp39 Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2032)

7.3 Global T Cell Antigen Gp39 Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 T Cell Antigen Gp39 Value Chain Analysis

8.1.1 T Cell Antigen Gp39 Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 T Cell Antigen Gp39 Production Mode & Process

8.2 T Cell Antigen Gp39 Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 T Cell Antigen Gp39 Distributors

8.2.3 T Cell Antigen Gp39 Customers

9 Global T Cell Antigen Gp39 Analyzing Market Dynamics

9.1 T Cell Antigen Gp39 Industry Trends

9.2 T Cell Antigen Gp39 Industry Drivers

9.3 T Cell Antigen Gp39 Industry Opportunities and Challenges

9.4 T Cell Antigen Gp39 Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global T Cell Antigen Gp39 Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global T Cell Antigen Gp39 Sales (K Units) of Manufacturers (2021-2026)
- Table 7: Global T Cell Antigen Gp39 Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global T Cell Antigen Gp39 Revenue of Manufacturers (2021-2026)
- Table 9: Global T Cell Antigen Gp39 Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market T Cell Antigen Gp39 Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global T Cell Antigen Gp39 Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of T Cell Antigen Gp39, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of T Cell Antigen Gp39, Product Type & Application
- Table 14: Global T Cell Antigen Gp39 Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global T Cell Antigen Gp39 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Biogen, Inc. Company Information
- Table 19: Biogen, Inc. Business Overview
- Table 20: Biogen, Inc. T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
- Table 22: Biogen, Inc. Recent Developments
- Table 23: XL-protein GmbH Company Information
- Table 24: XL-protein GmbH Business Overview
- Table 25: XL-protein GmbH T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
- Table 27: XL-protein GmbH Recent Developments
- Table 28: Targovax AS Company Information
- Table 29: Targovax AS Business Overview
- Table 30: Targovax AS T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: Targovax AS T Cell Antigen Gp39 Product Portfolio
- Table 32: Targovax AS Recent Developments
- Table 33: MedImmune, LLC Company Information
- Table 34: MedImmune, LLC Business Overview
- Table 35: MedImmune, LLC T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
- Table 37: MedImmune, LLC Recent Developments
- Table 38: Juno Therapeutics Inc. Company Information
- Table 39: Juno Therapeutics Inc. Business Overview
- Table 40: Juno Therapeutics Inc. T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
- Table 42: Juno Therapeutics Inc. Recent Developments
- Table 43: ImmuNext, Inc. Company Information
- Table 44: ImmuNext, Inc. Business Overview
- Table 45: ImmuNext, Inc. T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
- Table 47: ImmuNext, Inc. Recent Developments
- Table 48: eTheRNA Immunotherapies NV Company Information
- Table 49: eTheRNA Immunotherapies NV Business Overview

- Table 50: eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
- Table 52: eTheRNA Immunotherapies NV Recent Developments
- Table 53: Bristol-Myers Squibb Company Company Information
- Table 54: Bristol-Myers Squibb Company Business Overview
- Table 55: Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
- Table 57: Bristol-Myers Squibb Company Recent Developments
- Table 58: Global T Cell Antigen Gp39 Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 59: Global T Cell Antigen Gp39 Sales by Region (2021-2026) & (K Units)
- Table 60: Global T Cell Antigen Gp39 Sales Market Share by Region (2021-2026)
- Table 61: Global T Cell Antigen Gp39 Sales by Region (2027-2032) & (K Units)
- Table 62: Global T Cell Antigen Gp39 Sales Market Share by Region (2027-2032)
- Table 63: Global T Cell Antigen Gp39 Revenue by Region (2021-2026) & (US\$ Million)
- Table 64: Global T Cell Antigen Gp39 Revenue Market Share by Region (2021-2026)
- Table 65: Global T Cell Antigen Gp39 Revenue by Region (2027-2032) & (US\$ Million)
- Table 66: Global T Cell Antigen Gp39 Revenue Market Share by Region (2027-2032)
- Table 67: North America T Cell Antigen Gp39 Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 68: North America T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units)
- Table 69: North America T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units)
- Table 70: North America T Cell Antigen Gp39 Revenue by Country (2021-2026) & (US\$ Million)
- Table 71: North America T Cell Antigen Gp39 Revenue by Country (2027-2032) & (US\$ Million)
- Table 72: Europe T Cell Antigen Gp39 Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: Europe T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units)
- Table 74: Europe T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units)
- Table 75: Europe T Cell Antigen Gp39 Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: Europe T Cell Antigen Gp39 Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Asia Pacific T Cell Antigen Gp39 Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 78: Asia Pacific T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units)
- Table 79: Asia Pacific T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units)
- Table 80: Asia Pacific T Cell Antigen Gp39 Revenue by Country (2021-2026) & (US\$ Million)
- Table 81: Asia Pacific T Cell Antigen Gp39 Revenue by Country (2027-2032) & (US\$ Million)
- Table 82: South America T Cell Antigen Gp39 Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 83: South America T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units)
- Table 84: South America T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units)
- Table 85: South America T Cell Antigen Gp39 Revenue by Country (2021-2026) & (US\$ Million)
- Table 86: South America T Cell Antigen Gp39 Revenue by Country (2027-2032) & (US\$ Million)
- Table 87: Middle East and Africa T Cell Antigen Gp39 Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 88: Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units)
- Table 89: Middle East and Africa T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units)
- Table 90: Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2021-2026) & (US\$ Million)
- Table 91: Middle East and Africa T Cell Antigen Gp39 Revenue by Country (2027-2032) & (US\$ Million)
- Table 92: Global T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units)
- Table 93: Global T Cell Antigen Gp39 Sales by Type (2027-2032) & (K Units)
- Table 94: Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2026)
- Table 95: Global T Cell Antigen Gp39 Sales Market Share by Type (2027-2032)
- Table 96: Global T Cell Antigen Gp39 Revenue by Type (2021-2026) & (US\$ Million)
- Table 97: Global T Cell Antigen Gp39 Revenue by Type (2027-2032) & (US\$ Million)
- Table 98: Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2026)
- Table 99: Global T Cell Antigen Gp39 Revenue Market Share by Type (2027-2032)
- Table 100: Global T Cell Antigen Gp39 Price by Type (2021-2026) & (US\$/Unit)
- Table 101: Global T Cell Antigen Gp39 Price by Type (2027-2032) & (US\$/Unit)
- Table 102: Global T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units)
- Table 103: Global T Cell Antigen Gp39 Sales by Application (2027-2032) & (K Units)
- Table 104: Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2026)
- Table 105: Global T Cell Antigen Gp39 Sales Market Share by Application (2027-2032)
- Table 106: Global T Cell Antigen Gp39 Revenue by Application (2021-2026) & (US\$ Million)
- Table 107: Global T Cell Antigen Gp39 Revenue by Application (2027-2032) & (US\$ Million)
- Table 108: Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2026)
- Table 109: Global T Cell Antigen Gp39 Revenue Market Share by Application (2027-2032)
- Table 110: Global T Cell Antigen Gp39 Price by Application (2021-2026) & (US\$/Unit)
- Table 111: Global T Cell Antigen Gp39 Price by Application (2027-2032) & (US\$/Unit)
- Table 112: Key Raw Materials

- Table 113: Raw Materials Key Suppliers
- Table 114: T Cell Antigen Gp39 Distributors List
- Table 115: T Cell Antigen Gp39 Customers List
- Table 116: T Cell Antigen Gp39 Industry Trends
- Table 117: T Cell Antigen Gp39 Industry Drivers
- Table 118: T Cell Antigen Gp39 Industry Restraints
- Table 119: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: T Cell Antigen Gp39 Product Image
- Figure 5: Global T Cell Antigen Gp39 Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global T Cell Antigen Gp39 Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global T Cell Antigen Gp39 Sales (2021-2032) & (K Units)
- Figure 8: Global T Cell Antigen Gp39 Average Price (US\$/Unit) & (2021-2032)
- Figure 9: ECI-006 Product Image
- Figure 10: Hepatitis B Vaccine Product Image
- Figure 11: ISF-35 Product Image
- Figure 12: INX-021 Product Image
- Figure 13: Others Product Image
- Figure 14: Graft Versus Host Disease Product Image
- Figure 15: Pancreatic Cancer Product Image
- Figure 16: Breast Cancer Product Image
- Figure 17: Bladder Cancer Product Image
- Figure 18: Others Product Image
- Figure 19: Global T Cell Antigen Gp39 Revenue Share by Manufacturers in 2025
- Figure 20: Global Manufacturers of T Cell Antigen Gp39, Manufacturing Sites & Headquarters
- Figure 21: Global Top 5 and 10 T Cell Antigen Gp39 Players Market Share by Revenue in 2025
- Figure 22: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: Global T Cell Antigen Gp39 Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 24: Global T Cell Antigen Gp39 Sales by Region in 2025
- Figure 25: Global T Cell Antigen Gp39 Revenue by Region in 2025
- Figure 26: North America T Cell Antigen Gp39 Market Size by Country in 2025
- Figure 27: North America T Cell Antigen Gp39 Sales Market Share by Country (2021-2032)
- Figure 28: North America T Cell Antigen Gp39 Revenue Market Share by Country (2021-2032)
- Figure 29: United States T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Canada T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: Europe T Cell Antigen Gp39 Market Size by Country in 2025
- Figure 32: Europe T Cell Antigen Gp39 Sales Market Share by Country (2021-2032)
- Figure 33: Europe T Cell Antigen Gp39 Revenue Market Share by Country (2021-2032)
- Figure 34: Germany T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: France T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: U.K. T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Italy T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Netherlands T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Asia Pacific T Cell Antigen Gp39 Market Size by Country in 2025
- Figure 40: Asia Pacific T Cell Antigen Gp39 Sales Market Share by Country (2021-2032)
- Figure 41: Asia Pacific T Cell Antigen Gp39 Revenue Market Share by Country (2021-2032)
- Figure 42: China T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Japan T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: South Korea T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: India T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: Australia T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: China Taiwan T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Southeast Asia T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Southeast Asia T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: South America T Cell Antigen Gp39 Market Size by Country in 2025
- Figure 51: South America T Cell Antigen Gp39 Sales Market Share by Country (2021-2032)
- Figure 52: South America T Cell Antigen Gp39 Revenue Market Share by Country (2021-2032)
- Figure 53: Mexico T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Brazil T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 55: Argentina T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Middle East and Africa T Cell Antigen Gp39 Market Size by Country in 2025
- Figure 57: Middle East and Africa T Cell Antigen Gp39 Sales Market Share by Country (2021-2032)
- Figure 58: Middle East and Africa T Cell Antigen Gp39 Revenue Market Share by Country (2021-2032)
- Figure 59: Turkey T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Saudi Arabia T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: UAE T Cell Antigen Gp39 Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: Global T Cell Antigen Gp39 Sales Market Share by Type (2021-2032)
- Figure 63: Global T Cell Antigen Gp39 Revenue Market Share by Type (2021-2032)
- Figure 64: Global T Cell Antigen Gp39 Price (US\$/Unit) by Type (2021-2032)
- Figure 65: Global T Cell Antigen Gp39 Sales Market Share by Application (2021-2032)
- Figure 66: Global T Cell Antigen Gp39 Revenue Market Share by Application (2021-2032)
- Figure 67: Global T Cell Antigen Gp39 Price (US\$/Unit) by Application (2021-2032)
- Figure 68: T Cell Antigen Gp39 Value Chain
- Figure 69: T Cell Antigen Gp39 Production Mode & Process
- Figure 70: Direct Comparison with Distribution Share
- Figure 71: Distributors Profiles
- Figure 72: T Cell Antigen Gp39 Industry Opportunities and Challenges